Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 9/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1100922 | 0.89 | HSD11B1 (0.60) | HSD11B1MEN1KMT2ASMN1; SMN2OPRM1 | |
| SCHEMBL1100810 | 0.81 | HSD11B1 (0.55) | HSD11B1MAP3K5OPRM1OPRD1OPRK1 | |
| SCHEMBL1108945 | 0.80 | HSD11B1 (0.63) | HSD11B1 | |
| SCHEMBL1108955 | 0.77 | HSD11B1 (0.60) | HSD11B1 | |
| SCHEMBL1108820 | 0.77 | HSD11B1 (0.62) | HSD11B1MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1108944 | 0.75 | HSD11B1 (0.78) | HSD11B1 | |
| SCHEMBL1101035 | 0.74 | HSD11B1 (0.57) | HSD11B1 | |
| SCHEMBL1101068 | 0.74 | HSD11B1 (0.64) | HSD11B1 | |
| SCHEMBL1108947 | 0.72 | HSD11B1 (0.67) | HSD11B1MEN1KMT2AALDH1A1 | |
| SCHEMBL1108950 | 0.72 | HSD11B1 (0.64) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683059-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2010-03-23 | — | — | US | claimed |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | AMGEN SF LLC | 2008-10-09 | — | — | US | claimed |
| EP-1680114-A4 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC (US) | 2008-09-24 | — | — | EP | claimed |
| EP-1680114-A2 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | Amgen Inc. (US) | 2006-07-19 | — | — | EP | claimed |
| WO-2005044192-A2 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. (US) | 2005-05-19 | — | — | WO | claimed |
| US-8153631-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153631-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153631-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-7683059-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683059-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683059-B2 | Triazole compounds and uses related thereto | AMGEN INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. | 2010-03-11 | — | — | US | disclosed |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | AMGEN SF LLC | 2008-10-09 | — | — | US | disclosed |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | AMGEN SF LLC | 2008-10-09 | — | — | US | disclosed |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | AMGEN SF LLC | 2008-10-09 | — | — | US | disclosed |
| EP-1680114-A4 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1680114-A2 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | Amgen Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005044192-A2 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062972-A1 | TRIAZOLE COMPOUNDS AND USES RELATED THERETO | HSD11B1, HSD17B1, HSD17B3 | HSD11B1 1/4885MEN1 2815/4885CASP6 1725/4885 |
| US-20080249084-A1 | Triazole Compounds and Uses Related Thereto | GPR119, CYP11B2, CYP11B1 | HSD11B1 41/4885MEN1 2451/4885CASP6 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.